BELLUS Health Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from (used in) operating activities:
Net loss for the year
Adjustments for:
Depreciation
Stock-based compensation
Loss on lease modification
Net finance income, excluding realized effect of foreign exchange on operating assets and liabilities
Other items
Trade and other receivables
Research tax credits receivable
Prepaid expenses and other assets
Deferred tax asset
Trade and other payables
Current income tax liabilities
Net cash flows from (used in) operating activities
Cash flows from (used in) financing activities:
Issuance of common shares through 2022 Offering, net of share issue costs
Issuance of common shares through 2021 Offering, net of share issue costs
Share issue costs related to issuance of common shares to finance acquisition of in-process research and development asset (note 6)
Issuance of common shares - Proceeds received from exercise of stock options
Payment of deferred financing costs
Lease liability - principal repayments
Interest paid
Issuance of common shares through 2019 Offering, net of share issue costs
Issuance of common shares through 2018 Offering, net of share issue costs
Issuance of common shares upon stock options exercise
Net cash flows from (used in) financing activities

Cash flows from (used in) investing activities:
Purchases of short-term investments
Sales of short-term investments
Acquisition of in-process research and development asset, including transaction costs (note 6)
Interest received
Interest accrued
Net cash flows from (used in) investing activities

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
Effect of foreign exchange on cash and cash equivalents
Cash and cash equivalents, end of year
Supplemental cash flow disclosure:
Non-cash transactions:
Initial recognition of right-of-use asset and lease liability (note 5)
Additions to right-of-use asset and lease liability (note 5)
Issuance of common shares in consideration for acquisition of remaining BLU-5937 Assets (note 6)
Deferred financing costs, in Trade and other payables
Ascribed value related to issuance of common shares upon stock options exercise
Ascribed value related to issuance of common shares upon broker warrants exercise (note 8 (b) (ii))
Value of DSUs in prepaid expenses and other assets

Comments